The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
May. 24, 2016

Filed:

Jun. 25, 2012
Applicants:

Marc E. Rothenberg, Cincinnati, OH (US);

Julie Caldwell, Cincinnati, OH (US);

Inventors:

Marc E. Rothenberg, Cincinnati, OH (US);

Julie Caldwell, Cincinnati, OH (US);

Assignee:

Children's Hospital Medical Center, Cincinnati, OH (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/7088 (2006.01); A61K 31/713 (2006.01); A61K 39/395 (2006.01); A61K 48/00 (2006.01); C07K 16/18 (2006.01); C12N 15/11 (2006.01); C12N 15/113 (2010.01); C12Q 1/68 (2006.01); G01N 33/68 (2006.01);
U.S. Cl.
CPC ...
A61K 39/395 (2013.01); A61K 31/7088 (2013.01); A61K 31/713 (2013.01); A61K 48/00 (2013.01); C07K 16/18 (2013.01); C12N 15/11 (2013.01); C12N 15/113 (2013.01); C12Q 1/6881 (2013.01); C12Q 1/6883 (2013.01); G01N 33/6893 (2013.01); C07K 2319/30 (2013.01); C12N 2310/11 (2013.01); C12N 2310/141 (2013.01); C12N 2310/531 (2013.01); C12Q 2600/158 (2013.01);
Abstract

Embodiments of the invention are directed to methods of diagnosing eosinophilic gastritis (EG), or remission therefrom in a subject, wherein the methods include applying a sample from the subject to a diagnostic panel that contains selected markers for EG, analyzing the results thereof, and making a determination as to the EG status of the subject. Embodiments of the invention are also directed to methods of monitoring the pathological development or medical prognosis of EG in a subject. Embodiments of the invention are also directed to use of CDH26 as a marker for EG, eosinophilic esophagitis, or allergic inflammatory conditions. Embodiments of the invention also relate to the use of anti-CDH26-based therapeutics to treat allergic inflammatory conditions.


Find Patent Forward Citations

Loading…